What is new in 2019 ESC Clinical Practice Guidelines? Guidelines for the management of dyslipidaemia Review article
Article Sidebar
Published:
Dec 31, 2019
Keywords:
guidelines, dyslipidaemias, cholesterol LDL, statins, ezetimibe, PCSK9I, hipertrigliceridaemia
Main Article Content
Abstract
An update of the guidelines for the management of dyslipidaemia was released in 2019. First, this is needed to assess cardiovascular risk and to classify the patient into one of four cardiovascular risk groups. The class of recommendations for using of imaging techniques and assessment of lipids and lipoproteins (including apolipoprotein B and apolipoprotein A) in the assessment of global cardiovascular risk has been strengthened. Values of LDL cholesterol were significantly reduced for each of risk group. The role of ezetimibe and PCSK9 inhibitors was strengthened, and the role of combination therapy in the treatment of dyslipidaemia was increased.
Article Details
How to Cite
Ładak, P., Mrozińska, A., Sobieszek, A., Zamecka , E., & Kuch , M. (2019). What is new in 2019 ESC Clinical Practice Guidelines? Guidelines for the management of dyslipidaemia. Medycyna Faktow (J EBM), 12(4(45), 362-366. https://doi.org/10.24292/01.MF.0419.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Cybulska B., Kłosiewicz-Latoszek L., Szostak W.: Dyslipidemie. W: Interna Szczeklika. Mały Podręcznik 2019/20. Wydawnictwo Medycyna Praktyczna, Kraków 2019: 136-145.
2. Mach F., Baigent C., Catapano L. et al.: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2019; 00: 1-78. DOI: 10.1093/eurheartj/ehz455.
3. Catapano A., Graham I., Backer G. et al.: Wytyczne ESC/EAS dotyczące leczenia zaburzeń lipidowych w 2016 roku. Kardiol. Pol. 2016; 74(11): 1234-1318. DOI: 10.5603/KP.2016.0157.
2. Mach F., Baigent C., Catapano L. et al.: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2019; 00: 1-78. DOI: 10.1093/eurheartj/ehz455.
3. Catapano A., Graham I., Backer G. et al.: Wytyczne ESC/EAS dotyczące leczenia zaburzeń lipidowych w 2016 roku. Kardiol. Pol. 2016; 74(11): 1234-1318. DOI: 10.5603/KP.2016.0157.